Abstract:WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The search for a biomarker in overactive bladder syndrome (OAB) is an emerging field of interest, as bladder dysfunction is a common complaint that causes significant morbidity. A biomarker may give us insight as a diagnostic tool, and also inform us about how severe the condition is, how it may progress and how it may best be treated. The protein of interest here is nerve growth factor (NGF) and it has been shown to be a dynamic molecule in the bladder of patients with OAB. Urinary levels have been seen to rise in patients with OAB and fall in those who respond to treatment. However, there have also been many studies that examine this trend in numerous other conditions, e.g. interstitial cystitis, bladder outflow obstruction, renal stone disease and patients with neurological impairment after stroke. As a result the specificity of this as a potential urinary biomarker for OAB is questioned. This is a review of published studies, which discusses the pros and cons of NGF as a potential urinary biomarker. The evidence is examined and the studies are summarised together in a Table. Questions remain about the reliability, practicality and specificity of NGF as a biomarker for OAB. These questions need to be addressed by further studies that could clarify the points raised. Objective: To review the current literature on the use of urinary nerve growth factor (NGF) as a potential biomarker for overactive bladder syndrome (OAB). Method: A comprehensive electronic literature search was conducted using the PubMed database to identify publications relating to urinary NGF. Results: There are a growing number of publications that have measured urinary NGF levels in different types of bladder dysfunction. These range from OAB, bladder pain syndrome, idiopathic and neurogenic detrusor overactivity, bladder oversensitivity and bladder outflow obstruction. Urinary NGF levels do appear to be raised in these pathological states when compared with healthy control samples. In patients with OAB, these raised urinary NGF levels appear to also reduce after successful treatment with antimuscarinics and botulinum toxin A, which indicates a potential use in monitoring responses to treatment. However, raised levels are not limited to OAB, which questions its specificity. Urinary NGF measurements are performed with an enzyme-linked immunosorbent assay using polyclonal antibodies to NGF. The technique requires standardisation, and the different antibodies to NGF require validating. Also a definition of what is the 'normal' range of NGF in urine is still required before it can be used as a diagnostic and prognostic tool. Conclusions: Whilst the evidence for an increased urinary NGF in OAB appears convincing, many questions about its validity remain including: specificity, sensitivity, cost- and time-effectiveness. Many criteria for what constitutes a biomarker still need to be evaluated and met before this molecule can be considered for this role.

Change of Nerve Growth Factor Mrna in Human Detrusor in Bladder Outlet Obstruction with Benign Prostatic Hyperplasia and Their Implication

Changes of transforming growth factor-β of human detrusor after bladder outlet obstruction induced by benign prostatic hyperplasia

Changes of Basic Fibroblast Growth Factor in Bladder Smooth Muscle in Patients with Bladder Outlet Obstruction Induced by Benign Prostatic Hyperplasia

Basic fibroblast growth factor in human detrusor muscle in bladder outlet obstruction due to benign prostatic hyperplasia

Nerve Growth Factor Levels Are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia

Are TGF-beta(1) and Bfgf Correlated with Bladder Underactivity Induced by Bladder Outlet Obstruction?

[Relationship of Transforming Growth Factor Beta1 and Basic Fibroblast Growth Factor to Detrusor Underactivity Following Bladder Outlet Obstruction: Experiment with Rats].

Expression of basic fibroblast growth factor and transforming growth factor beta 1 in human bladder smooth muscle in BOO

Alterations of Urine TGF-beta 1 and Bfgf Following Bladder Outlet Obstruction: A Predictor for Detrusor Contractibility?

Expression of brainderived neurotrophic factor in urine of patients with benign prostatic hyperplasia complicated overactive bladder symptoms

Clinical significance of the expression of transforming growth factor-β1 and connective tissue growth factor in detrusor of benign prostatic hyperplasia patients

Comparative RNA-sequencing Analysis of the Prostate in a Mouse Model of Benign Prostatic Hyperplasia with Bladder Outlet Obstruction.

Changes in the Expression and Function of the PDE5 Pathway in the Obstructed Urinary Bladder

Association of Increased Urine Brain Derived Neurotrophic Factor with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia.

Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?

Changes in Alpha1-Adrenoceptor and NGF/proNGF Pathway: a Possible Mechanism in Diabetic Urethral Dysfunction.

EXPRESSION OF Bcl-2 Mrna IN NORMAL AND HYPERPLASTIC PROSTATE TISSUES

Urethral Meatus Stricture BOO Stimulates Bladder Smooth Muscle Cell Proliferation and Pyroptosis Via IL‑1β and the SGK1‑NFAT2 Signaling Pathway

Experimental Study of the Expression of Detrusor Myosin Heavy Chain Isoforms Following Bladder Outlet Obstruction

Relationship Between Bladder Outlet Obstruction and Serum Prostatic Specific Antigen in Patients with Benign Prostatic Hyperplasia

[Outcome of surgical management and pathogenesis of female primary bladder neck obstruction]